Bottom line
Is GBCIX a good fund? The bottom line
GBCIX is the Class I share class of The Gabelli Dividend Growth Fund, an actively managed dividend & equity income mutual fund from Innovator.
It charges 1% — about $100 a year on every $10,000 invested, more expensive than 73% of dividend & equity income funds we track.
It returned +18.8% over one year, +9.8% a year over five years, +9.4% a year over ten (as of Dec 31, 2025, per its prospectus).
With $21.8 million in net assets and 59 holdings, its largest position is Merck & Company Inc (5.3%) and the top 10 make up 31.8% of the portfolio.
What stands out
- No front-end sales load
What to watch
- Expensive for its category (1%)
- Small fund ($21.8 million) — small funds are likelier to close
Updated Nov 19, 2026
What GBCIX invests in
The Funds primary objective is to seek to provide long-term growth of capital. Current income is a secondary objective of the Fund.
Under normal market conditions, the Fund invests at least 80% of its net assets in dividend paying stocks. Dividend paying stocks include, for example, common stocks, preferred stocks, and convertible securities. In addition to seeking out stocks that pay a dividend, the Fund will focus on stocks that the portfolio manager believes are well positioned to increase their dividend over the long-term. In selecting investments, the portfolio manager will consider, among other things, the market price of the issuers securities, earnings expectations, dividend paying and other earnings and price histories, balance sheet characteristics, and perceived management skills. The portfolio manager will also consider changes in economic and political outlooks as well as individual corporate developments. For additional information about selection of investments suitable for the Fund, see page 9 of…
From the fund's prospectus (filed Apr 30, 2026).
GBCIX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| GBCIX | +18.8% | +9.8% | +9.4% |
| Dividend & Equity Income median | +14.6% | +10.1% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2025
What GBCIX costs
On a $10,000 investment, GBCIX's 1% expense ratio costs about $100 a year. The prospectus estimates $1,941 in total costs over 10 years (assuming 5% annual returns). The median dividend & equity income fund charges 0.74%.
GBCIX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Merck & Company Inc MRK | 5.30% |
| 2 | Amazon.com Inc AMZN | 4.15% |
| 3 | Alphabet Inc GOOG | 3.24% |
| 4 | Citigroup Inc C | 3.21% |
| 5 | Pnc Financial Services Group Inc (the) PNC | 3.16% |
| 6 | Mondelez International Inc MDLZ | 2.92% |
| 7 | Belden Inc BDC | 2.58% |
| 8 | American International Group Inc AIG | 2.56% |
| 9 | Cigna Group (the) CI | 2.53% |
| 10 | Ppl Corp PPL | 2.17% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 31.8% of the fund. See all top 25 holdings and asset mix →